Topic 23 · Everything else

Preclinical 15-PGDH Research & Emerging Therapies

Cartilage regeneration in mice and human explants, published in Science by a Stanford group. Still no registered human cartilage trial anywhere in the world.

→ The 15-PGDH findings are early laboratory research. They are scientifically interesting, but no human joint-treatment trial has established clinical benefit.

15-PGDH Inhibitor: Cartilage Regeneration Drug (Science, March 2026)

Stanford researchers published in Science that a small-molecule inhibitor of the enzyme 15-PGDH regenerates articular cartilage in aged mice and after joint injury [173]:

→ Mouse and ex-vivo human-tissue results cannot be assumed to work in a living human ankle. This research should not determine current surgical timing.

Added September 10, 2026 — the first paper to treat “how would this drug actually reach ankle cartilage?” as the question, and every answer lengthens the timeline

→ A drug that regrows cartilage in mice still has to physically get into human cartilage — which has no blood supply, is dense as rubber, and sits in a joint that flushes injected fluid out within hours. A new review works through that plumbing problem for the Stanford cartilage-regeneration target specifically. Its two sobering ideas: the enzyme the drug must block may live deepest in the cartilage, exactly where injected drugs penetrate worst; and some joints may be biologically past the point where regeneration can be switched on at all. Nothing here is measured yet — it is a framework — but it is the soberest published account of the distance between the mouse result and a human trial.

The entry above records what 15-PGDH inhibition did in mice [173]; a Journal of Controlled Release hypothesis review published this week is the first paper on this site to price out its delivery problem [470]. Its argument in four steps: (1) responsiveness likely requires a “cartilage-competent (index-responder)” joint — one that retains regenerative plasticity despite structural damage; (2) 15-PGDH activity is hypothesized to concentrate in deep cartilage, creating a depth-dependent enzymatic barrier precisely where drugs penetrate worst; (3) intra-articular injection faces a “clearance-diffusion mismatch” — the joint clears the drug faster than it can diffuse to deep-zone targets, so a joint can look adequately dosed while the target zone never sees inhibition; and (4) joint loading actively shapes drug transport, arguing for therapy staged into preconditioning, delivery, and retention phases.

What it is and is not: a single-author hypothesis review from an independent researcher — peer-reviewed framework, testable predictions, zero experiments — and it should be read as engineering questions, not findings. It earns its line here for two reasons. First, it converts this page’s vague “years away” into named, checkable obstacles: watch for papers measuring 15-PGDH’s depth distribution in human cartilage, or retention-engineered formulations, before believing any joint-trial timeline. Second, the index-responder idea cuts both ways for this file: a post-traumatic ankle with a defined start date and preserved joint space is a better candidate for “retained regenerative plasticity” than a decades-worn knee — but nobody can measure that phenotype yet. The standing conclusion is unchanged and strengthened: nothing in this class is close enough to justify deferring a surgical decision, and now there is a published list of reasons why.

Added August 13, 2026 — the field just published its own to-do list, and it opens by admitting the problem this site exists because of

→ The Arthritis Foundation and the foot-and-ankle surgeons’ society locked their best people in a room in January and asked: why does ankle arthritis have so few options, and what research would fix that within a decade? Their answer — a published roadmap — came out this morning.

The 2026 AOFAS/Arthritis Foundation Ankle Arthritis Think Tank (Napa, January 22, 2026) published its synthesis in Foot & Ankle Orthopaedics on August 13 [414]. The abstract’s framing could be this site’s epigraph: ankle OA “is predominantly post-traumatic in origin,” it “differs in important ways biologically, mechanically, and clinically from hip and knee OA,” and treatment “remain[s] largely reactive and centered on end-stage reconstruction” — convened, in its own words, “to solve patient frustration of limited treatment options.” Four sessions: biologic and biomechanical pathogenesis, diagnostic and management challenges, therapeutic strategies, and research methodology, closing on “actionable and fundable research pathways” for the next decade. The author list overlaps heavily with programs already on this site’s consult-and-watch lists — Schon, Ledoux, Ellis, Demetracopoulos (HSS), de Cesar Netto, Nancy Lane, Amendola (Duke).

What it is and is not: a priorities document, not a treatment — nothing in it changes a 2026 care decision. Its value here is directional: where these names put fundable priorities is where the next decade’s trials will come from. It is also, candidly, the strongest published statement yet that the frustration documented across this site is the field’s own assessment, not a patient’s misreading.

Updated August 17, 2026 — the full text opened, and the therapeutic-strategies session was worth the wait. The PMC deposit appeared within four days of publication, and the session this page cares about names three routes the abstract never mentioned [414]: (1) biologically augmented marrow stimulation — skeletal stem cells (a lineage distinct from generic MSCs) can be redirected toward cartilage after microfracture; in aged animal models, where plain regeneration fails, VEGF inhibition plus CCN3 restored cartilage formation — the panel’s read is that microfracture’s future is as a delivery event for biologics, not a standalone procedure (no human data yet); (2) intra-articular IL-1Ra gene therapy — the one entry with clinical numbers: early-phase studies show WOMAC pain reductions sustained to 104 weeks, and the panel frames it as a possible first disease-modifying biologic for ankle OA; (3) load modulation as disease modification — custom dynamic carbon-fiber orthoses cut pain up to 60% and peak contact stress ~20% (detail on topic 32). The closing discussion is equally blunt about orthobiologics: practice is running ahead of evidence, and the ankle field is ready for “placebo-controlled randomized trials with standardized biologic preparation protocols” — the trials whose absence topics 2 and 29 keep measuring.

Added August 14, 2026 — one day after the roadmap, a first attempt at the phenotyping it asked for

→ The roadmap said the field needs better ways to tell one ankle arthritis apart from another. The very next day, a review proposed exactly that: four named subtypes, and a list of instruments to measure them with.

A Frontiers in Medicine Mini Review published August 13 proposes an ankle-specific precision framework: four provisional baseline phenotypes — inflammatory-dominant, malalignment-dominant, post-traumatic/instability-dominant, and end-stage structural collapse — built from synovial-fluid biomarkers on one side and weight-bearing CT, automated 3D alignment metrics, gait analysis and plantar-pressure “digital signatures” on the other [419]. The argument for why the ankle can support this when the knee struggles to: ankle OA is enriched for post-traumatic mechanisms with a known start date, and its cartilage biology is measurably distinct from knee cartilage. Two things make it worth a line here rather than the exclusion a framework review would normally get: it reads as the working paper for the [414] roadmap’s diagnostics session, and its instrument list is the same one topic 28 has been arguing for from the patient side — quantitative alignment and loading assessment. Patient-record update, September 12: three standing ankle views were obtained August 20; quantified hindfoot/whole-leg alignment remains undocumented. A review proposes; it does not validate. The injury history is post-traumatic, but the new clinic notes report reassuring stability tests; they do not justify assigning an instability-dominant phenotype.

Added August 14, 2026 — the other half of the PGE2 story, and the 15-PGDH program will have to walk through it

→ The Stanford approach wants to raise a molecule called PGE2 to regrow cartilage. A new review assembles the evidence that the same molecule, acting on nerves in bone, is a driver of arthritis pain — and names ankle arthritis specifically. Both literatures can be right; a future drug has to satisfy both.

A Bone Research review of skeletal interoception — the sensory-nerve circuitry through which the skeleton reports its internal state — centers on PGE2 as the signal, and on ankle osteoarthritis as its worked example, citing adult ankle-pain prevalence of 9–15% [421]. In that literature, aberrant PGE2 signaling through sensory nerves in subchondral bone drives both abnormal remodeling and OA pain. Set beside the 15-PGDH entry at the top of this page, the tension is plain: 15-PGDH inhibition regenerates cartilage in mice by keeping PGE2 around longer; the interoception literature implicates sustained PGE2-sensory signaling in the pain of the same disease. These are different compartments — local matrix signaling versus nerve-mediated central circuits — so it is a design constraint, not a refutation. It is recorded because this site’s standing rule is to carry the evidence against its own hopes: any 15-PGDH joint trial will need pain outcomes watched as closely as cartilage volume. The review’s own therapeutic sections (acupuncture, from the authors’ department) are their research program, not evidence, and are not carried as such.

Added August 13, 2026 — a supplement-aisle molecule aimed at the fibrocartilage problem, in a dish

→ A Nanjing group found that betaine — sold over the counter as trimethylglycine — damps down a newly-identified fibrosis gene and steers cartilage cells back toward making the real, glassy kind of cartilage. In cells and animal models. This is a mechanism finding, not a reason to buy a bottle.

RNA-sequencing (bulk and single-cell) identified RARRES1 as a biomarker of cartilage fibrosis, confirmed upregulated in the damaged regions of human OA cartilage; in a chondrocyte-fibrosis model, betaine downregulated RARRES1, upregulated RGS2, cleared reactive oxygen species, and shifted repair toward hyaline rather than fibrotic tissue [415]. It joins 15-PGDH [173] and HRX-215/MKK4 [407] as a third distinct molecular route to the same target — the scar-tissue default that limits marrow stimulation. The gap between this and those two: HRX-215 has passed a human safety trial; betaine has human safety by virtue of being a food compound but no human joint data, no intra-articular or oral dosing evidence, and no registered trial. The rule stamped on every entry in this section applies unchanged: cells and rodents do not decide human treatment.

MKK4 Inhibition: A Human-Safety-Tested Drug Aimed at the Fibrocartilage Problem (August 2026)

A Peking University Third Hospital sports-medicine group reported that HRX-215, an oral MKK4 inhibitor, reduced cartilage fibrosis in a rat microfracture model as well as in a rat osteoarthritis model, while promoting proliferation and slowing oxidative-stress-driven matrix breakdown in human chondrocytes [407]:

→ Same rule as 15-PGDH above: rat results do not decide human treatment. The reason this one is worth a line is that the drug has already passed a human safety trial for a liver use, which shortens — but does not close — the distance to a cartilage trial. Nothing here should change surgical timing.

MACI Ankle Phase 3 Trial (MASCOT) — Now Enrolling

Vericel Corporation launched the first Phase 3 RCT comparing MACI vs bone marrow stimulation for symptomatic chondral/osteochondral lesions of the talus (ages 17-65) [174]:

Hy2Care CartRevive Hydrogel Implant

A naturally derived dextran + hyaluronic acid injectable that gels in ~60 seconds. FDA Breakthrough Device Designation + FDA IDE approval. First US patient treatment expected early 2026 [175]:

Costal Cartilage Transplantation (2025-2026)

Growing evidence for autologous costochondral transplantation for severe (Hepple V) OLT [176]:

Added August 12, 2026 — the comparative study arrived. The same Shanghai Sixth People’s program published the first head-to-head of costochondral transplantation (ACT) against osteoperiosteal transplantation (OPT) in Hepple V lesions: 53 ankles, 27 vs 26, and ACT led at every postoperative timepoint, with MOCART 2.0 still improving after 12 months in the ACT arm only [411]. Retrospective, single-center, and from the technique’s own inventors — and the ACT arm likely overlaps the [176] cohort above — but the rib graft now has comparative evidence against a named alternative, not just a case series. Full analysis on topic 26.

2026 four-year durability data, from the knee. A prospective single-arm follow-up of 40 patients treated with augmented microfracture using decellularized particulated costal allocartilage — processed donor rib cartilage rather than the patient's own rib — reported four-year outcomes [242]. The useful part is the shape of the curve rather than the numbers: MRI-assessed repair tissue quality peaked at two years (MOCART 58.3) and then declined modestly to 54.2 at four years (significantly below the two-year peak, but comparable to years one and three), while patient-reported outcomes held or kept improving, with several KOOS subscores still rising between years one and four. This is a knee study with no control arm and no ankle data, so it says nothing directly about a talar lesion. It is worth recording because it is a clean illustration of a pattern that recurs across cartilage repair: imaging quality and how the joint feels can move in opposite directions, which is a reason to be careful about reading a follow-up MRI as a verdict.

CARTILAGE Journal Special Issue: "Ankle Cartilage — New Beginnings" (March 2026)

An entire special issue of CARTILAGE dedicated to ankle OLT, edited by Kerkhoffs, Kennedy, Brittberg, and Dahmen [177]. Key messages:

Disease-Modifying OA Drugs (DMOADs): Pipeline Update

As of 2026, no DMOADs are FDA-approved for any joint. The pipeline:

The pattern worth noticing. Three independent lines converged within about a week in July 2026: TG-C, one of the furthest-advanced cell and gene therapies for joint disease, missed both co-primary endpoints in a 531-patient Phase 3; the scoping review of cell therapy for this exact condition found the human evidence base to be eleven non-randomised studies; and this review found no clinically validated peptide DMOAD. None of these is about a talar lesion specifically. Together they bear on one argument that genuinely could affect a decision here — that it is worth deferring surgery because an injectable disease-modifying therapy is nearly available. On the current evidence, nothing in this pipeline is close enough to justify waiting for it.